KalVista wants to raise $160M; Prime Medicine's upsized offering; Applied Tx's PhIII data
Plus, news about Intellia and ReCode:
KalVista aims to raise $160M following pivotal readout: Earlier this week, the company said its oral drug for hereditary angioedema helped relieve symptoms of the swelling attacks that come with the disease faster than placebo in a Phase III study. Now, it plans to sell roughly 7 million shares plus pre-funded warrants for nearly 3.5 million shares to raise $160 million. The biotech expects to submit the treatment, known as sebetralstat, for FDA approval in the first half of this year. — Lei Lei Wu
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
